John (Jack) Lawrence, M.D., is the Global Development Head of Cardiovascular & Metabolism (CVM) for Janssen Pharmaceutical Companies of Johnson & Johnson.
Jack is responsible for late stage clinical development for all cardiovascular and metabolic assets that transition from discovery and early development to late development. He also drives strategy for the identification and selection of promising external assets across the portfolio.
Jack is a trained cardiologist with specialty training in cardiac electrophysiology. He began his clinical practice at the John Hopkins University School of Medicine, treating patients with heart rhythm abnormalities. Prior to joining Janssen, he spent 17 years at Bristol-Myers Squibb where he served as vice president of cardiovascular business development. Most recently, he served as the chief medical officer for Portola Pharmaceutical where he was responsible for leading all product development, clinical and regulatory strategies and product approvals.
Jack received his Doctor of Medicine at the University of Virginia School of Medicine and completed his residency in Internal Medicine at the University of North Carolina School of Medicine. Prior to that, he earned his Bachelor of Science degree in Biomedical Engineering at Brown University and his Master of Science degree in Electrical Engineering at the Massachusetts Institute of Technology.